Valneva Travel Vaccines

Valneva travel vaccines stand out in the preventive health landscape, offering targeted protection for international travelers facing region-specific infectious risks. These vaccines address pathogens prevalent in tropical and developing regions, where standard childhood immunizations fall short.

Updated: 05/14/2026

By Elena Martinez, Senior Biotech Editor - covering vaccines and global health products.

What Valneva Travel Vaccines Are and How They Work

Valneva travel vaccines include Dukoral for cholera prevention and Ixiaro for Japanese encephalitis. Dukoral is an oral vaccine that stimulates the immune system to produce antibodies against Vibrio cholerae, the bacterium causing cholera diarrhea. Administered as a suspension mixed with water, it requires two doses taken one week apart, with a booster possible after three years for continued risk.

Ixiaro targets the Japanese encephalitis virus, transmitted by mosquitoes in rural Asia. This inactivated vaccine uses a Vero cell-based production method, delivering two doses over 28 days to build protective immunity lasting up to a year, with boosters extending coverage. Both vaccines undergo rigorous clinical testing to ensure safety and efficacy in adults and children over certain ages.

These products leverage Valneva's expertise in vaccine innovation, focusing on needle-free options where possible to improve compliance among travelers. Dukoral's oral format eliminates injection fears, making it accessible for those with needle phobia or in remote settings.

Why Valneva Travel Vaccines Matter for Consumers and Industry

For consumers, Valneva travel vaccines reduce the risk of severe illness during trips to high-risk areas. Cholera outbreaks in regions like sub-Saharan Africa and parts of Asia can sideline travelers with dehydration and hospitalization. Japanese encephalitis threatens over three billion people in endemic zones, with vaccines preventing thousands of cases annually among visitors.

Industry-wide, these vaccines fill gaps left by broader immunization programs. Travel medicine clinics rely on them for pre-trip consultations, while public health agencies recommend them for humanitarian workers and expatriates. Valneva's portfolio supports the $2 billion global travel vaccine market, growing with rising international mobility post-pandemic.

By prioritizing underserved diseases, Valneva contributes to global health equity, ensuring vaccines reach areas with limited local production capacity. This approach benefits pharmaceutical supply chains by diversifying beyond common flu or COVID shots.

Valneva Travel Vaccines in the Global Market

Demand for Valneva travel vaccines tracks international travel volumes, surging during peak vacation seasons and business expansions into Asia. Competition includes vaccines from Pfizer and Sanofi, but Valneva differentiates with its single-antigen focus and oral delivery for cholera. Regulatory approvals span the EMA, FDA, and WHO prequalification, enabling distribution in over 60 countries.

Supply chains emphasize cold-chain logistics to maintain potency, with manufacturing in Europe meeting cGMP standards. Adoption patterns show high uptake among adventure tourists and corporate travelers, with studies confirming 70-85% efficacy rates against targeted diseases.

Challenges include variable reimbursement policies across markets, yet growing awareness drives prescriptions. Valneva's partnerships with travel health networks enhance accessibility at airports and clinics.

Valneva SE develops and commercializes these travel vaccines as part of its infectious disease portfolio. The company focuses on vaccines for unmet needs in travel medicine.

Valneva shares trade on Euronext Paris under ISIN FR0013280286. Investors track the firm's pipeline progress and regulatory milestones.

Disclaimer: This article is not investment advice. Stocks are volatile financial instruments.